Elevance Health, Inc. $ELV Shares Acquired by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC boosted its position in Elevance Health, Inc. (NYSE:ELV) by 3.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,247 shares of the company’s stock after buying an additional 1,278 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Elevance Health were worth $14,102,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. GLOBALT Investments LLC GA lifted its holdings in Elevance Health by 0.4% in the 1st quarter. GLOBALT Investments LLC GA now owns 6,306 shares of the company’s stock worth $2,743,000 after buying an additional 24 shares in the last quarter. Elser Financial Planning Inc lifted its holdings in Elevance Health by 3.0% in the 1st quarter. Elser Financial Planning Inc now owns 882 shares of the company’s stock worth $384,000 after buying an additional 26 shares in the last quarter. Checchi Capital Advisers LLC lifted its holdings in Elevance Health by 1.0% in the 1st quarter. Checchi Capital Advisers LLC now owns 2,737 shares of the company’s stock worth $1,190,000 after buying an additional 27 shares in the last quarter. Hemington Wealth Management lifted its holdings in Elevance Health by 13.3% in the 1st quarter. Hemington Wealth Management now owns 230 shares of the company’s stock worth $100,000 after buying an additional 27 shares in the last quarter. Finally, Aspen Investment Management Inc lifted its holdings in Elevance Health by 2.6% in the 1st quarter. Aspen Investment Management Inc now owns 1,048 shares of the company’s stock worth $456,000 after buying an additional 27 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $353.29 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $510.24. The firm has a 50-day simple moving average of $315.10 and a 200 day simple moving average of $358.68. The company has a market cap of $79.55 billion, a PE ratio of 15.03, a P/E/G ratio of 1.29 and a beta of 0.59.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Thursday, July 17th. The company reported $8.84 earnings per share for the quarter, missing analysts’ consensus estimates of $9.30 by ($0.46). Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The business had revenue of $49.42 billion for the quarter, compared to the consensus estimate of $48.26 billion. During the same period in the prior year, the company earned $10.12 EPS. Elevance Health’s quarterly revenue was up 14.3% on a year-over-year basis. On average, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 25th. Investors of record on Wednesday, September 10th were given a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend was Wednesday, September 10th. Elevance Health’s dividend payout ratio is currently 29.11%.

Analysts Set New Price Targets

ELV has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their price objective on shares of Elevance Health from $330.00 to $412.00 and gave the stock an “overweight” rating in a report on Tuesday. Robert W. Baird dropped their target price on shares of Elevance Health from $492.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. JPMorgan Chase & Co. dropped their target price on shares of Elevance Health from $472.00 to $384.00 and set an “overweight” rating for the company in a research report on Tuesday, July 22nd. Barclays boosted their target price on shares of Elevance Health from $373.00 to $395.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Guggenheim boosted their target price on shares of Elevance Health from $360.00 to $398.00 and gave the stock a “buy” rating in a research report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $412.00.

Insider Transactions at Elevance Health

In other Elevance Health news, CEO Gail Boudreaux acquired 8,500 shares of the stock in a transaction that occurred on Friday, July 18th. The stock was acquired at an average price of $286.94 per share, with a total value of $2,438,990.00. Following the transaction, the chief executive officer directly owned 151,020 shares in the company, valued at approximately $43,333,678.80. This represents a 5.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Susan D. Devore acquired 1,200 shares of the stock in a transaction that occurred on Tuesday, August 19th. The shares were acquired at an average cost of $312.15 per share, with a total value of $374,580.00. Following the transaction, the director owned 3,502 shares in the company, valued at approximately $1,093,149.30. The trade was a 52.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.29% of the stock is owned by corporate insiders.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.